JP2022534813A5 - - Google Patents

Info

Publication number
JP2022534813A5
JP2022534813A5 JP2022515977A JP2022515977A JP2022534813A5 JP 2022534813 A5 JP2022534813 A5 JP 2022534813A5 JP 2022515977 A JP2022515977 A JP 2022515977A JP 2022515977 A JP2022515977 A JP 2022515977A JP 2022534813 A5 JP2022534813 A5 JP 2022534813A5
Authority
JP
Japan
Prior art keywords
cells
cell population
grna
sequence
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022515977A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022534813A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/034391 external-priority patent/WO2020237217A1/en
Publication of JP2022534813A publication Critical patent/JP2022534813A/ja
Publication of JP2022534813A5 publication Critical patent/JP2022534813A5/ja
Pending legal-status Critical Current

Links

JP2022515977A 2019-05-23 2020-05-22 Cd33改変のための組成物および方法 Pending JP2022534813A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962852238P 2019-05-23 2019-05-23
US62/852,238 2019-05-23
US202062962127P 2020-01-16 2020-01-16
US62/962,127 2020-01-16
PCT/US2020/034391 WO2020237217A1 (en) 2019-05-23 2020-05-22 Compositions and methods for cd33 modification

Publications (2)

Publication Number Publication Date
JP2022534813A JP2022534813A (ja) 2022-08-03
JP2022534813A5 true JP2022534813A5 (cg-RX-API-DMAC7.html) 2023-05-24

Family

ID=71078652

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022515977A Pending JP2022534813A (ja) 2019-05-23 2020-05-22 Cd33改変のための組成物および方法

Country Status (9)

Country Link
US (1) US20220228153A1 (cg-RX-API-DMAC7.html)
EP (1) EP3973057A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022534813A (cg-RX-API-DMAC7.html)
KR (1) KR20220035877A (cg-RX-API-DMAC7.html)
CN (1) CN114423865A (cg-RX-API-DMAC7.html)
AU (1) AU2020280103A1 (cg-RX-API-DMAC7.html)
CA (1) CA3141732A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021014306A (cg-RX-API-DMAC7.html)
WO (1) WO2020237217A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102709603B1 (ko) * 2017-02-28 2024-09-27 보르 바이오파마 인크. 계통 특이적 단백질의 억제를 위한 조성물 및 방법
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
US20230407337A1 (en) * 2020-12-08 2023-12-21 The Regents if the University of California Crispr ribonucleoprotein complex genome editing of human innate immune cells
WO2023283585A2 (en) 2021-07-06 2023-01-12 Vor Biopharma Inc. Inhibitor oligonucleotides and methods of use thereof
EP4381062A1 (en) 2021-08-02 2024-06-12 Vor Biopharma Inc. Compositions and methods for gene modification
WO2024015925A2 (en) 2022-07-13 2024-01-18 Vor Biopharma Inc. Compositions and methods for artificial protospacer adjacent motif (pam) generation
WO2024073751A1 (en) 2022-09-29 2024-04-04 Vor Biopharma Inc. Methods and compositions for gene modification and enrichment
WO2025030010A1 (en) 2023-08-01 2025-02-06 Vor Biopharma Inc. Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
EP3129485B2 (en) 2014-04-09 2022-12-21 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating cystic fibrosis
CA2969619A1 (en) 2014-12-03 2016-06-09 Agilent Technologies, Inc. Guide rna with chemical modifications
CN107787367B (zh) 2015-04-06 2021-10-26 里兰斯坦福初级大学理事会 用于crispr/cas介导的基因调控的化学修饰的引导rna
WO2017053729A1 (en) * 2015-09-25 2017-03-30 The Board Of Trustees Of The Leland Stanford Junior University Nuclease-mediated genome editing of primary cells and enrichment thereof
IL258491B2 (en) * 2015-10-16 2023-09-01 Univ Columbia Preparations and methods for inhibiting antigens of a particular lineage
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
CN110249052B (zh) 2016-12-30 2024-04-12 爱迪塔斯医药公司 合成的指导分子、组合物和与其相关的方法
KR102709603B1 (ko) 2017-02-28 2024-09-27 보르 바이오파마 인크. 계통 특이적 단백질의 억제를 위한 조성물 및 방법
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
IL306092A (en) 2017-03-23 2023-11-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
EP3676372A4 (en) * 2017-08-28 2021-06-02 The Trustees of Columbia University in the City of New York CD33 EXON 2 DEFICIENT DONOR STEM CELLS FOR USE WITH AGENTS AGAINST CD33
CA3110837A1 (en) * 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
SG11202103832SA (en) * 2018-11-07 2021-05-28 Crispr Therapeutics Ag Anti-cd33 immune cell cancer therapy
JP7784707B2 (ja) * 2019-01-16 2025-12-12 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 系統特異的抗原の阻害のための組成物および方法

Similar Documents

Publication Publication Date Title
JP2022520138A5 (cg-RX-API-DMAC7.html)
US11639523B2 (en) Type V CRISPR-Cas systems and use thereof
JP7094323B2 (ja) 最適化機能CRISPR-Cas系による配列操作のための系、方法および組成物
Slattery et al. An expanded plasmid-based genetic toolbox enables Cas9 genome editing and stable maintenance of synthetic pathways in Phaeodactylum tricornutum
AU2015342749B2 (en) Methods for improving CRISPR/Cas-mediated genome-editing
JP2023508740A5 (cg-RX-API-DMAC7.html)
WO2022140577A2 (en) Compositions and methods for epigenetic editing
JP2023541457A5 (cg-RX-API-DMAC7.html)
US20250304934A1 (en) Reprogrammable fanzor polynucleotides and uses thereof
Chen et al. In vivo prime editing by lipid nanoparticle co-delivery of chemically modified pegRNA and prime editor mRNA
JP2022538084A5 (cg-RX-API-DMAC7.html)
Amoasii et al. In vivo non-invasive monitoring of dystrophin correction in a new Duchenne muscular dystrophy reporter mouse
CN109207477A (zh) 新型crispr酶以及系统
CA3204429A1 (en) Dna nuclease guided transposase compositions and methods of use thereof
Xu et al. CRISPR/Cas9-related technologies in liver diseases: from feasibility to future diversity
Yang et al. CRISPR Cas9 in pancreatic cancer research
CN117136235A (zh) 用于表观遗传编辑的组合物和方法
US20230383272A1 (en) Nucleic acid-guided nucleases and use thereof
JP2023528415A5 (cg-RX-API-DMAC7.html)
JP2024534387A5 (cg-RX-API-DMAC7.html)
US20260008827A1 (en) Nuclease-guided non-ltr retrotransposons and uses thereof
CN105624196A (zh) 一种建立cyp2c11基因敲除大鼠模型的方法
Mukushkina et al. In silico prediction of miRNA interactions with candidate atherosclerosis gene mRNAs
JP2022502481A (ja) 遺伝的に変異された細胞の死滅誘導組成物及び該組成物を用いた遺伝的に変異された細胞の死滅誘導方法
JP2024528202A5 (cg-RX-API-DMAC7.html)